Logo
x

Search

Subscribe Now

venous thromboembolism

Janssen Reports Submission of NDA to the US FDA for Xarelto (rivaroxaban) to Prevent and Treat Blood Clots in Children

Janssen Reports Submission of NDA to the US FDA for Xarelto (rivaroxaban) to Prevent and Treat Blood Clots in Children

  • June 24, 2021
Bayer Reports Submission of MAA to EMA for Rivaroxaban to Treat Venous Thromboembolism in Children

Bayer Reports Submission of MAA to EMA for Rivaroxaban to Treat Venous Thromboembolism in Children

  • November 26, 2019
Bayer and Janssen's Xarelto (rivaroxaban) Receive FDA's Approval to Prevent Venous Thromboembolism in Acutely Ill Patients

Bayer and Janssen's Xarelto (rivaroxaban) Receive FDA's Approval to Prevent Venous Thromboembolism in Acutely Ill Patients

  • October 15, 2019
Bayer Reports Results of Xarelto (rivaroxaban) in P-III EINSTEIN-Jr. Study for Venous Thromboembolism

Bayer Reports Results of Xarelto (rivaroxaban) in P-III EINSTEIN-Jr. Study for Venous Thromboembolism

  • July 9, 2019
Boehringer Ingelheim Reports Results of Pradaxa (dabigatran etexilate mesylate) for the Management of Venous Thromboembolism in Children

Boehringer Ingelheim Reports Results of Pradaxa (dabigatran etexilate mesylate) for the Management of Venous Thromboembolism in Ch...

  • July 9, 2019
Pfizer's Fragmin (dalteparin sodium) Receives FDA's Approval for Symptomatic Venous Thromboembolism in Pediatric Patients

Pfizer's Fragmin (dalteparin sodium) Receives FDA's Approval for Symptomatic Venous Thromboembolism in Pediatric Patients

  • May 17, 2019
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.